Nanomedicine: Ethical Issues and Societal Expectations
Speaker: PD Dr Johann S. Ach Academic Coordinator, Centre for Advanced Study in Bioethics, University of Mnster (D) CLINAM 7/ 2014, 7th Conference and Exhib...
By: TAUVOD
See the rest here:
Nanomedicine: Ethical Issues and Societal Expectations - Video
Personalized Cancer Nanomedicine
Speaker: Prof. Dr. med. Simo Schwartz, Jr., PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM), Vall...
By: TAUVOD
Original post:
Personalized Cancer Nanomedicine - Video
The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics
Speaker: Prof. Dr. Alberto A. Gabizon, Hebrew University - School of Medicine - Shaare Zedek MC Oncology Institute, Jerusalem (IL) CLINAM 7/ 2014, 7th Confer...
By: TAUVOD
Read more from the original source:
The EPR Effect and its Relevance to Nanomedicine and Cancer Therapeutics - Video
The Regulation Environment in Nanomedicine and Targeted Medicine
CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.
By: TAUVOD
Visit link:
The Regulation Environment in Nanomedicine and Targeted Medicine - Video
Nanomedicine characterization at NCI #39;s Nanotechnology Characterization Lab (NCL)
Speaker: Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute (USA) CLINAM 7/ 2014, 7th Conference and Exhibi...
By: TAUVOD
Go here to see the original:
Nanomedicine characterization at NCI's Nanotechnology Characterization Lab (NCL) - Video
Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development
Speaker: Dr. Cristianne JF Rijcken, PharmD, CEO, Cristal Delivery B.V., Maastricht (NL) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.
By: TAUVOD
Go here to see the original:
Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development - Video
Nanomedicine in Malaria Treatment
Speaker: Paula Melariri CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.
By: TAUVOD
See the rest here:
Nanomedicine in Malaria Treatment - Video
Top Nanomedicine researcher Dr. Mark Dewhirst speaks at OSU
Mark W. Dewhirst, DVM, PhD, is one of the top researchers in the field of nanomedicine. He is known for developing the thermally sensitive liposome that was ...
By: OStateTV
Go here to read the rest:
Top Nanomedicine researcher Dr. Mark Dewhirst speaks at OSU - Video
London, UK (PRWEB) March 05, 2015
The emergence of nanotechnology has greatly impacted the clinical therapeutics landscape over the past decade. The pharmaceutical world has witnessed advancements in biocompatible nanoscale carriers for drug delivery in the form of liposomes and polymeric nanoparticles that are capable of delivering manifold drugs with more safety and efficiency. In the area of cancer therapeutics, the nanoparticles could perhaps rely greatly upon the enhanced permeability and retention (EPR) effect induced by leaky tumour vasculatures for a better accumulation of drugs at the tumour sites. Due to these benefits, the therapeutic nanoparticles in this respect have grown into a very promising field with the potential to successfully take the place of traditional chemotherapy.
The development of nanoparticle drug delivery systems for the treatment of cancer is set to become a lucrative field in the years to come. The protein polymers from natural sources emerge as up-and-coming materials for building the nanocarrier systems. The commercial success of albumin-based nanoparticles has also generated great interest in other proteins. With the rational design of protein nanoparticles on the grounds of their behaviours in the tumour microenvironment and based on the cell biology of cancer, enhanced cancer treatment efficacy and safety can be achieved.
Topical report Cancer Nanomedicine Market & Pipeline Insight 2015 worked out by Kuick Research is now available at MarketPublishers.com.
Report Details:
Title: Cancer Nanomedicine Market & Pipeline Insight 2015 Published: February, 2015 Pages: 220 Price: US$ 2,000.00 http://marketpublishers.com/report/diagnostics-diseases/cancer/cancer-nanomedicine-market-pipeline-insight-2015.html
The report offers an essential guide to the worldwide cancer nanomedicine marketplace. It provides deep insights into the role of nanomedicine in cancer therapies, contains a detailed classification of cancer nanoparticles drug delivery systems, looks at the mechanism of tumour nanomedicine treatment. The study presents a deep overview of the cancer nanomedicine clinical development pipeline, looking at it based on indication, stage and company. It reviews the 79 candidates in clinical development, the 8 marketed cancer nanomedicine drugs. The competitive landscape is canvassed as well including a discussion of the 11 leading companies. The report casts light on the market dynamics covering key drivers and commercialisation challenges, besides speculating on the future prospects of the market.
Companies reviewed comprise: Abraxis BioScience, Alnylam Pharmaceuticals, Access Pharmaceuticals, Bind Biosciences, Samyang, Arrowhead Research, Epeius Biotechnologies, Nanobiotix, Nippon Kayaku, NanoCarrier, and Takeda Pharmaceutical.
Report Highlights:
More topical studies by the publisher can be found at Kuick Research page.
The rest is here:
Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com
The need for the discovery and development of innovative technologies to improve the delivery of therapeutic and diagnostic agents in the body is widely recognized. The next generation therapies must be able to deliver drugs, therapeutic proteins and recombinant DNA to focal areas of disease or to tumors to maximize clinical benefit while limiting untoward side effects. The use of nanoscale technologies to design novel drug delivery systems and devices is a rapidly developing area of biomedical research that promises breakthrough advances in therapeutics and diagnostics.
Center for Drug Delivery and Nanomedicine (CDDN) serves to unify existing diverse technical and scientific expertise in biomedical and material science research at the University of Nebraska thereby creating a world class interdisciplinary drug delivery and nanomedicine program. This is realized by integrating established expertise in drug delivery, gene therapy, neuroscience, pathology, immunology, pharmacology, vaccine therapy, cancer biology, polymer science and nanotechnology at the University of Nebraska Medical Center (UNMC), the University of Nebraska at Lincoln (UNL) and Creighton University.
CDDNs vision is to improve health by enhancing the efficacy and safety of new and existing therapeutic agents, diagnostic agents and genes through the discovery and application of innovative methods of drug delivery and nanotechnology. CDDNs mission is to discover and apply knowledge to design, develop and evaluate novel approaches to improve the delivery of therapeutic agents, diagnostic agents and genes.
The COBRE Nebraska Center for Nanomedicine is supported by the National Institute of General Medical Science(NIGMS) grant 2P20 GM103480-07.
Laurent Levy, CEO of Nanobiotix, commented: "We really appreciate that Professor Langer joined us as a Scientific Advisor. Professor Langer is a globally acknowledged nanomedicine expert and serial business innovator, and his involvement will be an asset for our technologies, our development and expansion beyond cancer".
Professor Langer presides over the largest academic biomedical engineering laboratory in the world. His laboratory is centered in the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. His team has more than 100 researchers including chemists, biologists, materials science engineers and computer scientists.
He is also a Principle Investigator at the MIT-Harvard Center for Cancer Nanotechnology Excellence, one of eight Centers of Cancer Nanotechnology Excellence awarded by The National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Beyond his extensive involvement and leadership in MIT's scientific community, Professor Langer's research has spawned a vast array of innovative and disruptive technologies. He holds over 1,000 patents in diverse areas of biomedical technology and has been involved in the launch or acceleration of numerous biotech companies including BIND Therapeutics, Enzytech and Pervasis as examples.
Professor Langer said: "Radical and disruptive technologies are always required. An interdisciplinary approach to research and development is critical to ensure that these technologies are developed to their fullest potential. I see NanoXray technology as one of the technologies that could make a significant difference to disease treatment. Nanobiotix has very exciting and innovative projects and I look forward to working with the Team".
In September 2014, Nanobiotix opened its US affiliate in the Boston Life Science hub, in Cambridge MA. The location provides access to a critical mass of academic and medical institutions as well as biopharmaceutical industries, and will ensure access to the research community and clinical expertise in the US.
About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September, 2014.
Visit link:
Professor Robert Langer joins Nanobiotix as Scientific Advisor
The Nanomedicine Toolkit
https://store.theartofservice.com/the-nanomedicine-toolkit.html This innovative set of documents and ready-to-use templates will provide you with a head star...
By: TheArtofService
Continue reading here:
The Nanomedicine Toolkit - Video
Profiles in Nanomedicine Research: Mallapragada
By: ISUengineering
See the original post here:
Profiles in Nanomedicine Research: Mallapragada - Video
In Nanovision by Paul T. Harry, we are introduced to the subject of nanotechnology or nanomedicine, the medical application of that technology.
A devastating murder and betrayal leaves one person dead and a young teen without both his father and vision due to the fire used to cover up that murder. Daniel wakes up in the hospital with no vision and no memories. He doesn't remember his life before his pain and has nowhere to go.
Upon further search, an aunt that has cut off ties long in the past is located. She is involved in the field of Nanomedicine and works in research. Not sure she is capable of taking on such a tragic young man, she nevertheless does her best. Ethyl Santini is raising her granddaughter and leads a very busy life of research in a nanolab where she is at work on regeneration. The testing of animals has proved to be extremely workable, and she has been able to save many that would not have lived otherwise.
In her heart she knows that she must help Daniel, and while she had not been aware she had a nephew, she is up to the challenge. Armed with her granddaughter's approval she brings him into her family. Aware that while to the outside world he has been declared dead, there are concerns that he may still not be safe.
The fit is perfect, and Ethyl is thrilled to find Daniel so likable. As he bonds with her younger charge life seems to be just right. Yet now her lab is in trouble, and she is uneasy about her own research. Knowing she could be ousted at any time, she does the unimaginable. She puts together a new formula for her own nephew. With his agreement, they begin a series of doses to see if nanotechnology can help his eyesight. None of them are prepared for the changes.
As Daniel's regeneration begins, his memory resurfaces, as well as anger at the death of his father and the assault on himself. Heading back to his home he is after the very man who changed his life. Judy, the FBI special investigator that followed the crime and found his aunt, is notified, and she begins the hunt to find him, for she knows more about this crime then he understands. Can she locate him before he finds those responsible? She is very aware that if he comes upon them first, he will not survive for they have been in the business of death for a long time. With his sudden disappearance, can she find him before it is too late?
Harry has given us characters that are interesting and likable. His use of technology is an interesting foil and creates a plausible storyline. The action and undertakings seem very real and are much like some of the crimes we see reported in the news, yet he takes us on a rocky journey of home and nanomedicine.
His interpretation of the reactions as Daniel's blindness recedes is amazing, and the action and interplay is sharp. You find the possibilities for exciting and strange. He has given us an intriguing thriller full of danger and excitement, and threaded it with the possibility of medical miracles.
If you enjoy action, mystery and suspense with just a touch of the unbelievable you will find this a great book for your library. Once you begin, plan on a full day of reading; this work is difficult to put down.
View the original article on blogcritics.org
Read the original here:
Book Review: 'Nanovision,' A Technological Thriller by Paul T. Harry
What it's all about
The recent emergence of nanoscience as a key approach to innovation in advanced materials has sparked a similar interest in the application of its principles to the fields of biomedical diagnostics, therapeutics, and basic cell physiology.
The overarching goal of the new St Louis Institute of Nanomedicine sponsored by the Missouri Life Sciences Research Board is to advance the safe and effective use of nanotechnologies to reduce death and suffering from human disease.
The St. Louis Institute for Nanomedicine is a joint venture sponsored principally by leading local academic institutions that will assemble a broad base of regional expertise in the nanotechnology, medicine, technology transfer, and education to create novel solutions to complex health care problems.
Founding partners include: WashingtonFounding partners include: Washington University, University of Missouri at St Louis, St Louis University, and the St Louis Community Colleges. The Institute will develop viable approaches to foster collaborations between multinational industrial and regional academic partners, and seek to leverage local financial and community resources to grow the regional biotechnology enterprise.
Regulatory News:
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris with effect as from January 28, 2015, thanks to its stock market capitalization increase performances during 2014.
Compartment B groups together listed companies with a stock market capitalization of between 150 million and 1 billion euros. For the record, the average market capitalization of Nanobiotix over the last 60 trading days in 2014 was 249 million euros.
This transfer has no impact on the inclusion of Nanobiotix shares to NYSE Euronext indexes.
Laurent Levy, CEO of Nanobiotix comments: Following our admission to the SRD label in December, we are proud to announce the transfer of our shares from compartment C to compartment B of the regulated market of Euronext in Paris. This transfer rewards the dynamism and stock market performance of Nanobiotix during 2014. This operation and the strong increase of Nanobiotix shares liquidity with more than 1 billion 300 million euros traded this year, should improve the visibility of Nanobiotix to the international financial and industrial communities.
Compartment transfers were officially announced to market members by means of a notice to the market from Euronext on January 26, with an effective date of January 28, 2015.
Next financial press release: revenue for the 4thquarter of 2014 by February 27, 2015
About NANOBIOTIX: http://www.nanobiotix.com/fr
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers including Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, Head and Neck Cancer, Glioblastoma, Prostate Cancer, etc., via multiple routes of administration.
IMAGE:Professor Dimitrios Stamou heads a team specializing in investigating single cells and cell membranes along with a multidisciplinary team from Bio-Nanotechnology and Nanomedicine Laboratory, Nano-Science Center, Department of Chemistry, University... view more
Credit: Photo: Jes Andersen/University of Copenhagen.
The findings of Professor Dimitrios Stamou, Post Doc Jannik Bruun Larsen and a multidisciplinary team from Bio-Nanotechnology and Nanomedicine Laboratory, Nano-Science Center, Department of Chemistry are published under the title "Membrane curvature enables N-Ras lipid anchor sorting to liquid-ordered membrane phases" in the highly respected journal Nature Chemical Biology.
Ras-proteins inhabit the interior wall of each and every cell in the human body. Their role is to activate cell division or cell growth, so cancers develop if the protein starts to permanently trigger cells to grow and split: A process known as misregulation.
Ras misregulates if it misses its correct location on the cell wall; its membrane. What Stamou and Larsen discovered is that Ras cannot reach its designated location if the membrane has the wrong shape, explains Professor Dimitrios Stamou.
"If the curvature of the cell is right, Ras goes to the right place. If the membrane is too straight or too bent, it does not. And Ras is very much like any other worker. If it never finds the way to its work place, it is not likely to get any work done", says Stamou.
Ras are thought to be misregulated in upwards of 30 % of all cancers and is specifically linked to highly lethal strains in lungs, colon and pancreas. For three decades researchers have been searching for ways to quench the killer protein. Their lack of success has given Ras a reputation as the "undruggable cancer target" so Stamou is suggesting to head off in an entirely new direction.
"If Ras goes off the rails because of changes in the curvature of the cell, perhaps we should target whatever changes the shape of the cell membrane, says professor Stamou and goes on: "This is a change of perspective similar to when we went from flying with hot air balloons to taking off with fixed wings and propellers".
Looking for a correlation between cell shape and Ras misregulation was unusual bordering on controversial, says Jannik Bruun Larsen. The team was investigating how the proteins attach themselves to the cell wall and Larsen tried to attach Ras to a variety of simulated cell membranes formed into small spheres or vesicles of varying sizes. Ras would attach more readily to smaller balls. These are more curved than large and Larsen started to see a pattern.
"For more than a decade people thought that the constituents of the cell wall was the thing that controlled where Ras was localized, . We have shown, that at least one other aspect, namely membrane curvature, governs where Ras ends up in the cell and is therefore likely to be a factor in cancer development,", says the jubilant Post Doc, Jannik Bruun Larsen.
Read the original:
New strategy to combat 'undruggable' cancer molecule
DGAP-News: MagForce AG / Key word(s): Regulatory Admission MagForce AG: MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission
27.01.2015 / 08:00
---------------------------------------------------------------------
MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission
Berlin, Germany and Nevada, USA, January 27, 2015 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discuss FDA's response to MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission of November, 2014.
"We received very constructive feedback on our submission and have an understanding of the pathway to market in the USA of NanoTherm(TM) Therapy to focally ablate prostate cancer. MagForce USA, Inc. will accelerate the prostate cancer Investigational Device Exemption (IDE) to utilize the MFH 300F NanoActivator(R) for both Glioblastoma and Prostate NanoTherm(TM) Therapy registration," commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.
For more information, please visit: http://www.magforce.com.
See the rest here:
DGAP-News: MagForce AG: MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting on MagForce's NanoTherm(TM ...
Ethical, Legal, Social and Economic Aspects of Nanomedicine
Lecture of Dr. Klaus-Michael Weltring, Chair of WG Eyhics in ETPN. The lecture was performed at the Training Workshop on Ethical Issues in Nanomedicine, the ...
By: Michael Beigel
Excerpt from:
Ethical, Legal, Social and Economic Aspects of Nanomedicine - Video
WEST HAVEN, Conn., Jan. 23, 2015 /PRNewswire/ --NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
No direct adverse clinical effects were found upon administration of the FluCide candidate intravenously at doses of up to 300mg/kg/day for 14 days (a total of 4,200mg/kg) in rats. Organs were examined for gross histological observations. Microscopic histological tissue analysis was also performed. There were no adverse histological findings in gross organ level histological examination, nor were there any adverse findings in microscopic histological analysis. Equally importantly, there were no meaningful effects observed on animal weight gain, food consumption, hematology, or clinical chemistry at the end of the 14 day dosing period.
The study was conducted at BASi (Bioanalytical Systems, Inc., NASDAQ: BASI) in Evansville, Indiana. The study was performed in a cGLP-like fashion, compliant with BASi Evansville standard operating procedures. BASi has over 40 years of experience providing contract research services and niche instrumentation to the life sciences, primarily drug research and development.
These results are in agreement with the previously reported results of a non-GLP toxicology study in mice. The current study results also support the Company's positive findings in animal models of infection with different influenza A virus strains in which no safety or toxicology concerns were observed. The Company has previously reported that many of its FluCide candidates demonstrated extremely high anti-influenza activity in those models.
This study was developed in collaboration with BASi and conducted by BASi in a cGLP-like fashion in order to understand the safety parameters of FluCide intravenous dosing.
The next phase of the toxicology package studies will involve larger animals, and will require much larger quantities of the drug candidate. The Company is in the process of commissioning operations at the new 1 Controls Drive, Shelton, CT facility in order to perform the scale up studies needed for making the large quantities of materials in a controlled manner. These upcoming studies will be performed in cGLP compliant manner to provide safety and toxicology data that are required for an IND submission to regulatory agencies.
About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
SOURCE NanoViricides, Inc.
Read the rest here:
NanoViricides Reports that the FluCide Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study ...